CRO for CNS Drug Development
Although QPS is complying with all government regulations for social distancing and allowing employees who can, to work from home, QPS Neuropharmacology is up and running. Please feel free to contact us any time to discuss your research needs.
Welcome to QPS Neuropharmacology
QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Orphan Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.
Why Choose Us?
- Customer satisfaction is our absolute priority
- Your timeline is our timeline
- Every study is custom-built
- Scientific input to study design and data interpretation
- Extensive experience with virtually all drug targets and treatment types
- Wide range of validated models and techniques for comprehensive compound tests from a single source
- AAALAC certification ensures highest quality standards
Latest News
TSPO as sensitive biomarker for neuroinflammation in the Huntingon’s disease mouse model R6/2
Neuroinflammation is a growing field of research in the fight against neurodegenerative diseases and other disorders affecting the central nervous system. TSPO is an outer mitochondrial membrane protein, that has recently raised some interest for research in Huntington’s disease since its upregulation has been associated with the activation of glia cells. By labelling GFAP, Iba1, and TSPO in the cortex of 8 and 15 week old R6/2 mice we show that immunolabeling of astrocytes is increased in 15 week old R6/2 mice while microglia do not change (A, B). Analysis of TSPO shows an increased immunoreactive area in R6/2 mice already at the age of 8 weeks that further increases at 15 weeks (C).
Figure 1. Neuroinflammation in R6/2 mice. Percent of cortical immunoreactive area covered by GFAP (A, astrocytes), Iba1 (B, microglia), and TSPO (C). Note the increase of GFAP and TSPO in older R6/2 mice. D and E: Immunofluorescence images show the expression of TSPO (green) in glia cells (red), examples show astrocytes in the corpus callosum (D) and microglia in the fornix (E).